Completed PHASE1 INTERVENTIONAL NCT00134134

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

Sponsor: Genentech, Inc.

Conditions Hidradenitis Suppurativa

Interventions efalizumab

Updated 6 times since 2017 Last updated: Sep 7, 2006 Started: Feb 28, 2005 Completion: Aug 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hidradenitis Suppurativa, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jun 2019 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
NYU Langone Health

Data source: NYU Langone Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States